Article
Mesoblast shares tank after US FDA rejects cell therapy for children
Rating:
0.0
Views:
60
Likes:
1
Library:
1
The U.S. health regulator rejected Mesoblast's , cell therapy for children under 12 years of age for treating a type of complication that occurs after a stem cell or bone marrow transplant, sending its Australia-listed shares crashing about 58% on Friday.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value